Share:
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena's clinical pipeline.
"Hideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company," said Gene Kinney, PhD, President and Chief Executive Officer. "His experience leading several late-stage development programs in neurology and rare disease indications through registration and launch is particularly relevant as we advance our pipeline of programs in these areas. We are delighted to welcome him to the team as we prepare for our next stage of growth."